Cantor Fitzgerald initiated coverage on Cabaletta Bio with a new price target
$CABA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cantor Fitzgerald initiated coverage of Cabaletta Bio with a rating of Overweight and set a new price target of $40.00